Continuing Research Clause Samples
Continuing Research. Within 6 months of Project authorization the Operator(s) will fund and the BLM will select a consultant to initiate a study researching the potential impacts of dust on rock art in Nine Mile Canyon. While a more detailed research design will be developed by the consultant, at a minimum, the study will investigate what constituents are present in various dust samples taken from rock art panels, and whether the dust is causing physical degradation of the rock art.
Continuing Research.
(a) By letter dated [**], Foundation called a special meeting of the JSC pursuant to Second Amendment Section 2(g) to address the Cost/Timeline Issue that a [**] by the [**] of [**] and that the [**] of $[**] before a [**] would be [**]. As contemplated by Second Amendment Section 2(g)(1) the JSC has agreed upon the Corrective Plan and related budget that are attached as Exhibits TA-1 and TA-2, respectively. Such Corrective Plan and related budget constitutes an amendment of the Research Plan and related budget. Company shall conduct the DC Research in accordance with the Agreement, as amended.
(b) In connection with adoption of the Corrective Plan, the JSC has also agreed upon the DC Criteria attached as Exhibit TA-3 and the parties have agreed to extend the DC Timeline Goal to [**] and the Research Term until the earliest of (i) the date upon which the JSC first designates a Development Candidate, (ii) [**] or (iii) the effective date of any termination of the Research Term pursuant to Second Amendment Section 3. If a Development Candidate is not selected by the extended DC Timeline Goal, the parties shall have the right to call a special meeting of the JSC to address [**] in accordance with Second Amendment Section [**], including by agreeing upon [**], and if applicable thereafter, the rights specified in Section Amendment Section 2(h) and/or Second Amendment Section [**].
(c) Notwithstanding Second Amendment Section 2(d), Company shall be responsible for funding one hundred percent (100%) of the total overall cost of all DC Research performed on or after the Third Amendment Effective Date; provided, however, that Company shall have the ability to set its own budgets with respect to the conduct of the research after [**] so long as the Company’s obligations under Section 2.5 of the Agreement (captioned “Performance Standards”) are met. Company acknowledges and agrees that Foundation has paid all amounts due to Company pursuant to Second Amendment Section 2(d) and does not have any further obligation to reimburse Company for any amounts incurred by Company, whether before or after the Third Amendment Effective Date, with respect to the DC Research. If Foundation decides in its discretion to engage [**] or other external contract research organizations (“CROs”) or academic collaborators [**] to test, after the Third Amendment Effective Date, any compounds arising from the DC Research, Foundation shall be solely responsible for paying any amounts owed...
Continuing Research. Development and Commercialization of ReoPro. ---------------------------------------------------------------- Notwithstanding anything in the Agreement, or any correspondence or discussions entered into in connection therewith, Centocor and Lilly hereby agree that all costs and expenses as described in Article VII and Exhibit A of the Agreement incurred after the date of this Amendment in connection with the continued research, development and commercialization of ReoPro in the Territory, including, but not limited to, costs and expenses of clinical studies for xxxxxxxxxx shall be shared xxxxxxxxxxx by Centocor and Lilly in accordance with the xxxxxxxxxx sharing system described in Article VII and Exhibit A of the Agreement. Notwithstanding the foregoing, all cost sharing as described in this Amendment and the Agreement shall be limited to those costs related to plans approved by the Product Committee.
Continuing Research. Development and Commercialization of ReoPro. Notwithstanding anything in the Agreement, or any correspondence or discussions entered into in connection therewith, Centocor and Lilly hereby agree that all costs and expenses as described in Article VII and Exhibit A of the Agreement incurred after the date of this Amendment in connection with the continued research, development and commercialization of ReoPro in the Territory, including, but not limited to, costs and expenses of clinical studies for XXXXXXXXXX shall be shared XXXXXXXXXX by Centocor and Lilly in accordance with the XXXXXXXXXX sharing system described in Article VII and Exhibit A of the Agreement. Notwithstanding the foregoing, all cost sharing as described in this Amendment and the Agreement shall be limited to those costs related to plans approved by the Product Committee.